US2012165356A1PendingUtilityA1
Spirocyclic heterocyclic derivatives and methods of their use
Est. expiryOct 1, 2023(expired)· nominal 20-yr term from priority
A61P 37/02A61P 41/00A61P 9/06A61P 9/00A61P 9/10A61P 37/06A61P 43/00A61P 37/08A61P 9/12A61P 25/24A61P 25/08A61P 25/28A61P 25/32A61P 27/06A61P 31/12A61P 25/00A61P 25/14A61P 25/22A61P 25/34A61P 25/16A61P 25/04A61P 25/36A61P 25/30A61P 31/04A61P 29/00A61P 25/18A61P 25/20A61P 11/00C07D 493/10C07D 311/96C07D 491/107A61P 13/02C07D 221/20A61P 1/00A61P 15/00A61P 23/00A61P 11/14C07D 495/10A61P 15/10C07D 401/04A61P 1/04A61P 19/02A61P 13/00A61P 17/06A61P 11/06A61P 15/12A61K 31/438C07D 491/10
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.
Claims
exact text as granted — not AI-modified1 - 148 . (canceled)
149 . A method for preventing or treating a urogenital tract disorder, comprising the step of:
administering to a patient in need thereof an effective amount of a compound of the following formula:
or a pharmaceutically acceptable salt or N-oxide thereof.
150 . A method according to claim 149 ,
wherein said urogenital tract disorder is incontinence or overactive bladder.
151 . A method according to claim 150 , wherein said incontinence is stress urinary incontinence or urge urinary incontinence.
152 . A method according to claim 150 , wherein said urogenital tract disorder is overactive bladder.
153 . A method according to claim 150 further comprising the step of:
administering to said patient an effective amount of an agent for the treatment of incontinence.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.